Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novavax ICC Vaccine Phase 1/2 Study
NCT04961541Phase 2Completed
- Sponsor
- Novavax
- Start
- Sep 2021
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of qNIV + CoV2373 in coronavirus disease 2019 (COVID-19) and influenza (14 arms), sponsored by Novavax. Primary endpoints: Solicited Local and Systemic Adverse Events, Unsolicited Adverse Events and 1 more. Started Sep 2021; status: completed.
02
Drugs
qNIV + CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT04961541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04961541.